Methylnaltrexone (Relistor) for opioid-induced constipation

American Family Physician

Volumn 82, Issue 6, 2010, Pages 678-679

  Crownover, Brian ^a   Zimmerman, Ethan ^a  

^a Nellis Air Force Base   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 METHYLNALTREXONE BROMIDE; LAXATIVE; MORPHINE; OPIATE; OSMOTIC AGENT; PLACEBO;

ABDOMINAL PAIN; CONSTIPATION; DIARRHEA; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; INTESTINE TRANSIT TIME; NAUSEA; REVIEW;

EID: 79956315408     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Review

References (5)

1. Relistor (methylnaltrexone bromide) subcutaneous injection [prescribing information]. Philadelphia, Pa.: Wyeth Pharmaceuticals; Revised May 2010. http://www.wyeth.com/content/showlabeling.asp?id=499. Accessed July 9, 2010.
2. Chamberlain BH, Cross K, Winston JL, et al. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. J Pain Symptom Manage. 2009;38(5):683-690.
3. Portenoy RK, Thomas J, Moehl Boatwright ML, et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage. 2008;35(5):458-468.
4. Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008;358(22):2332-2343.
5. Clemens KE, Klaschik E. Managing opioid-induced constipation in advanced illness: focus on methylnaltrexone bromide. Ther Clin Risk Manag. 2010;6:77-82.